Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $31.29, demonstrating a +2.93% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq added 0.09%. The stock of company has risen by 5.01% in the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37%.The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company is expected to report EPS of -$0.44, down 120% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.86 per share and revenue of $25 million, which would represent changes of -84.16% and 0%, respectively, from the prior year. It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 32% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks